Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large b-cell lymphoma. N Engl J Med. 2018;378(15):1396–407. https://doi.org/10.1056/NEJMoa1801445.
Article CAS PubMed PubMed Central Google Scholar
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90. https://doi.org/10.1038/s41591-018-0016-8.
Article CAS PubMed PubMed Central Google Scholar
Nair RR, Tolentino JH, Hazlehurst LA. Role of STAT3 in transformation and drug resistance in cml. Front Oncol. 2012;2:30. https://doi.org/10.3389/fonc.2012.00030.
Article PubMed PubMed Central Google Scholar
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, volume 2. 4th ed. Lyon: International agency for research on cancer; 2017.
Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study. Haematologica. 2019;105(9):2308–15. https://doi.org/10.3324/haematol.2019.231076.
Article CAS PubMed Central Google Scholar
Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106(5):1770–7. https://doi.org/10.1182/blood-2005-02-0542.
Article CAS PubMed Google Scholar
Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med. 1998;188(12):2301–11. https://doi.org/10.1084/jem.188.12.2301.
Article CAS PubMed PubMed Central Google Scholar
Blaize G, Daniels-Treffandier H, Aloulou M, Rouquie N, Yang C, Marcellin M, et al. CD5 signalosome coordinates antagonist TCR signals to control the generation of Treg cells induced by foreign antigens. Proc Natl Acad Sci USA. 2020;117(23):12969–79. https://doi.org/10.1073/pnas.1917182117.
Article CAS PubMed PubMed Central Google Scholar
Yoshimoto M. The ontogeny of murine B-1a cells. Int J Hematol. 2020;111(5):622–7. https://doi.org/10.1007/s12185-019-02787-8.
Article CAS PubMed Google Scholar
Youinou P, Renaudineau Y. The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev. 2007;7(2):149–54. https://doi.org/10.1016/j.autrev.2007.02.016.
Article CAS PubMed Google Scholar
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y, et al. Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5(+) DLBCL. Br J Haematol. 2018;183(4):661–4. https://doi.org/10.1111/bjh.15001.
Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21(10):2069–74. https://doi.org/10.1093/annonc/mdq057.
Article CAS PubMed Google Scholar
Machida H, Shinohara T, Hatakeyama N, Okano Y, Nakano M, Tobiume M, et al. CD5-positive diffuse large B cell lymphoma infiltrating the central nervous system presenting Guillain-Barre-like syndrome after chemotherapy. J Clin Exp Hematop. 2012;52(3):199–204. https://doi.org/10.3960/jslrt.52.199.
Miyazaki K. CD5-positive DLBCL: molecular basis and treatment strategies. Rinsho Ketsueki. 2015;56(8):1038–44. https://doi.org/10.11406/rinketsu.56.1038. (Japanese).
Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601–7. https://doi.org/10.1093/annonc/mdq627.
Article CAS PubMed Google Scholar
Kakimoto Y, Ito S, Abiru H, Kotani H, Ozeki M, Tamaki K, et al. Sorbin and SH3 domain-containing protein 2 is released from infarcted heart in the very early phase: proteomic analysis of cardiac tissues from patients. J Am Heart Assoc. 2013;2(6): e000565. https://doi.org/10.1161/JAHA.113.000565.
Article CAS PubMed PubMed Central Google Scholar
Kakimoto Y, Tsuruyama T, Yamamoto T, Furuta M, Kotani H, Ozeki M, et al. Novel in situ pretreatment method for significantly enhancing the signal in MALDI-TOF MS of formalin-fixed paraffin-embedded tissue sections. PLoS ONE. 2012;7(8): e41607. https://doi.org/10.1371/journal.pone.0041607.
Article CAS PubMed PubMed Central Google Scholar
Kiso K, Yoshifuji H, Oku T, Hikida M, Kitagori K, Hirayama Y, et al. Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus patients. PLoS ONE. 2017;12(9): e0184738. https://doi.org/10.1371/journal.pone.0184738.
Article CAS PubMed PubMed Central Google Scholar
Miyagawa-Hayashino A, Yoshifuji H, Kitagori K, Ito S, Oku T, Hirayama Y, et al. Increase of MZB1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes. Arthritis Res Ther. 2018;20(1):13. https://doi.org/10.1186/s13075-018-1511-5.
Article CAS PubMed PubMed Central Google Scholar
Salah A, Yoshifuji H, Ito S, Kitagori K, Kiso K, Yamada N, et al. High expression of Galectin-3 in patients with IgG4-related disease: a proteomic approach. Patholog Res Int. 2017;2017:9312142. https://doi.org/10.1155/2017/9312142.
Article PubMed PubMed Central Google Scholar
Sun R, Lyu M, Liang S, Ge W, Wang Y, Ding X, et al. A prostate cancer tissue specific spectral library for targeted proteomic analysis. Proteomics. 2022;22(7): e2100147. https://doi.org/10.1002/pmic.202100147.
Article CAS PubMed Google Scholar
Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, et al. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics. 2005;4(11):1741–53. https://doi.org/10.1074/mcp.M500102-MCP200.
Article CAS PubMed Google Scholar
Zhang Z, Grabchak M. Nonparametric estimation of Kullback-Leibler divergence. Neural Comput. 2014;26(11):2570–93. https://doi.org/10.1162/NECO_a_00646.
Maeda A, Scharenberg AM, Tsukada S, Bolen JB, Kinet JP, Kurosaki T. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene. 1999;18(14):2291–7. https://doi.org/10.1038/sj.onc.1202552.
Article CAS PubMed Google Scholar
Engels N, Konig LM, Schulze W, Radtke D, Vanshylla K, Lutz J, et al. The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module. Nat Commun. 2014;5:5456. https://doi.org/10.1038/ncomms6456.
Article CAS PubMed Google Scholar
Almaghrbi H, Elkardawy R, Udhaya Kumar S, Kuttikrishnan S, Abunada T, Kashyap MK, et al. Analysis of signaling cascades from myeloma cells treated with pristimerin. Adv Protein Chem Struct Biol. 2023;134:147–74. https://doi.org/10.1016/bs.apcsb.2022.10.006.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, et al. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. Mol Cancer. 2021;20(1):134. https://doi.org/10.1186/s12943-021-01437-0.
Article CAS PubMed PubMed Central Google Scholar
Mo J, Liang H, Su C, Li P, Chen J, Zhang B. DDX3X: structure, physiologic functions and cancer. Mol Cancer. 2021;20(1):38. https://doi.org/10.1186/s12943-021-01325-7.
Article CAS PubMed PubMed Central Google Scholar
Dobashi A, Tsuyama N, Asaka R, Togashi Y, Ueda K, Sakata S, et al. Frequent BCOR aberrations in extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2016;55(5):460–71. https://doi.org/10.1002/gcc.22348.
Article CAS PubMed Google Scholar
Zhang Y, Li C, Xue W, Zhang M, Li Z. Frequent mutations in natural killer/T cell lymphoma. Cell Physiol Biochem. 2018;49(1):1–16. https://doi.org/10.1159/000492835.
Article CAS PubMed Google Scholar
Ok CY, Xu-Monette ZY, Tzankov A, O’Malley DP, Montes-Moreno S, Visco C, et al. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014;120(12):1818–29. https://doi.org/10.1002/cncr.28664.
Article CAS PubMed Google Scholar
Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood. 2011;118(18):4919–29. https://doi.org/10.1182/blood-2011-07-364224.
Comments (0)